metastasis-directed treatment

RADIATION2 trials

Sponsors

University Hospital, Ghent

Conditions

Metastatic CancerOligometastasisOligometastatic CancerProstate CancerProstate Cancer MetastaticProstate Cancer Recurrent

Phase 2

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

Active, not recruitingNCT03569241

University Hospital, GhentMetastatic Cancer, Oligometastatic Cancer, Prostate Cancer +1

Start: 2018-04-27End: 2026-12-31Updated: 2024-12-09

Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer

RecruitingNCT04641078

University Hospital, GhentMetastatic Cancer, Oligometastasis, Prostate Cancer +2

Start: 2021-02-12End: 2026-02-12Target: 124Updated: 2024-02-28

Related Papers

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

2026-01-20

Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.

2025-05-0524 citations

PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.

2023-10-0922 citations

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

2020-09-1432 citations

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BMC Cancer2020-06-0132 citations

PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

2020-05-1264 citations

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

JAMA Oncology2020-03-261068 citations